Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences, Inc (PLSE)
Last pulse biosciences, inc earnings: 11/7 03:42 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.pulsebiosciences.com
Company Research
Source: Business Wire
Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA.Key study findings include:100% procedural success of evaluable patients at 6 months (75/75)96% procedural success of evaluable patients at one year (45/47)Average number of applications were 16.1 ± 5.2 per procedureTotal procedure and fluoroscopy times were 65 ± 28 and 9.8 ± 5.8 minutes, respectivelyLeft atrial dwell time
Show less
Read more
Impact Snapshot
Event Time:
PLSE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLSE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLSE alerts
High impacting Pulse Biosciences, Inc news events
Weekly update
A roundup of the hottest topics
PLSE
News
- Pulse Biosciences (NASDAQ:PLSE) was given a new $30.00 price target on by analysts at Mizuho.MarketBeat
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026Business Wire
- Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF SymposiumBusiness Wire
- Pulse Biosciences (NASDAQ:PLSE) is now covered by analysts at Mizuho. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
PLSE
Earnings
- 11/5/25 - Beat
PLSE
Sec Filings
- 2/6/26 - Form 4
- 2/6/26 - Form 3
- 2/6/26 - Form 8-K
- PLSE's page on the SEC website